Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma

Molecular Cancer Therapeutics

Volumn 9, Issue 7, 2010, Pages 2037-2045

  Gros, Stephanie J ^a   Kurschat, Nina ^a   Dohrmann, Thorsten ^a   Reichelt, Uta ^a   Dancau, Ana Maria ^a   Peldschus, Kersten ^a   Adam, Gerhard ^a   Hoffman, Robert M ^b,c   Izbicki, Jakob R ^a   Kaifi, Jussuf T ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; ESOPHAGUS CARCINOMA; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INBRED MOUSE STRAIN; LYMPHATIC METASTASIS; METASTASIS; NUDE MOUSE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED STRAINS; MICE, NUDE; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954590442     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0209     Document Type: Article

References (56)

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
2. Normanno N, Bianco C, Strizzi L, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6:243-57.
3. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett 2005;227:9-23.
4. Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 2003;34:362-8.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
6. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 2001;37 Suppl 4:S16-22.
7. Leyland-Jones B. Trastuzumab: hopes and realities. Lancet Oncol 2002;3:137-44.
8. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-70.
9. Tuma RS. Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 2005;97:870-1.
10. Kollmannsberger C, Pressler H, Mayer F, Kanz L, Bokemeyer C. Cisplatin-refractory, HER-2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. Ann Oncol 1999;10:1393-4.
11. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 2004;22:1180-7.
12. Locati LD, Rinaldi G, Bossi P, et al. Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer. Oral Oncol 2005; 41:97-8.
13. al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-9.
14. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG. The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg 1995;221:677-83.
15. Flejou JF, Paraf F, Muzeau F, et al. Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994;47:23-6.
16. Friess H, Fukuda A, Tang WH, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 1999;23:1010-8.
17. Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, Sarbia M. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 2002; 118:60-6.
18. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D. c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. J Clin Pathol 1995;48:129-32.
19. Hardwick RH, Barham CP, Ozua P, et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997;23:30-5.
20. Jankowski J, Coghill G, Hopwood D, Wormsley KG. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992;33:1033-8.
21. Kim R, Clarke MR, Melhem MF, et al. Expression of p53, PCNA, C-erbB-2 in Barrett's metaplasia and adenocarcinoma. Dig Dis Sci 1997;42:2453-62.
22. Nakamura T, Nekarda H, Hoelscher AH, et al. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 1994;73:1785-94.
23. Safran H, Dipetrillo T, Nadeem A, et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004;22:670-7.
24. Sauter ER, Keller SM, Erner S, Goldberg M. HER-2/neu: a differentiation marker in adenocarcinoma of the esophagus. Cancer Lett 1993;75:41-4. (Pubitemid 24012706)
25. Trudgill NJ, Suvarna SK, Royds JA, Riley SA. Cell cycle regulation in patients with intestinal metaplasia at the gastro-oesophageal junction. Mol Pathol 2003;56:313-7.
26. Walch A, Bink K, Gais P, et al. Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal Cell Pathol 2000;20:25-32.
27. Walch A, Specht K, Bink K, et al. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia- adenocarcinoma sequence of Barrett's esophagus. Lab Invest 2001;81:791-801.
28. Akamatsu M, Matsumoto T, Oka K, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2003;57:1323-7.
29. Lam KY, Tin L, Ma L. C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol 1998;24:431-5.
30. Mimura K, Kono K, Hanawa M, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005;92:1253-60.
31. Suo Z, Holm R, Nesland JM. Squamous cell carcinomas. An immunohistochemical study of cytokeratins and involucrin in primary and metastatic tumours. Histopathology 1993;23:45-54.
32. Suo Z, Su W, Holm R, Nesland JM. Lack of expression of c-erbB-2 oncoprotein in human esophageal squamous cell carcinomas. Anti-cancer Res 1995;15:2797-8. (Pubitemid 26095102)
33. Suwanagool P, Parichatikanond P, Maeda S. Expression of c-erbB-2 oncoprotein in primary human tumors: an immunohistochemistry study. Asian Pac J Allergy Immunol 1993;11:119-22. (Pubitemid 24151615)
34. Reichelt U, Duesedau P, Tsourlakis MC, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007;20:120-9.
35. Gros SJ, Dohrmann T, Peldschus K, et al. Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model. Int J Cancer 2010; 126:2671-81.
36. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999;91:1758-64.
37. Schraml P, Kononen J, Bubendorf L, et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 1999;5:1966-75.
38. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999;17:343-59.
39. Hoffman RM. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol Med 2005;111:297-322.
40. Francia G, Man S, Lee CJ, et al. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res 2009;15:6358-66.
41. Gee MS, Upadhyay R, Bergquist H, et al. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology 2008;248:925-35.
42. Pratesi G, Petrangolini G, Tortoreto M, et al. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 2008;31:537-44.
43. Rossi E, Grisanti S, Villanacci V, et al. HER-2 overexpression/ amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J Cell Mol Med 2009;13:3826-33.
44. Villanacci V, Rossi E, Grisanti S, et al. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol Dietol 2008; 54:347-53.
45. Safran H, Dipetrillo T, Akerman P, et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER-2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67:405-9.
46. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56:3666-9. (Pubitemid 26272010)
47. Kawaguchi Y, Kono K, Mimura K, et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007;97: 494-501.
48. Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 2001;20:1913-22.
49. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody- dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 2005;11:4898-904.
50. Dahlberg PS, Jacobson BA, Dahal G, et al. ERBB2 amplifications in esophageal adenocarcinoma. Ann Thorac Surg 2004;78: 1790-800.
51. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101:810-6.
52. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor longterm survival in breast cancer. Int J Cancer 1991;49:650-5.
53. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004;22:3608-17.
54. Montemurro F, Sarotto I, Casorzo L, Pisacane A, Aglietta M, De RG. HER-2 and central nervous system metastasis in patients with breast cancer. Clin Breast Cancer 2004;5:232-4. (Pubitemid 40124465)
55. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18: 2349-51.
56. Zhang GH, Yang WT, Zhou XY, Zeng Y, Lu HF, Shi DR. Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer. Zhonghua Yi Xue Za Zhi 2007;87:155-60.